The Comparative Oncology Trials Consortium: Using Spontaneously Occurring Cancers in Dogs to Inform the Cancer Drug Development Pathway
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The Health in Action section is a forum for individuals or organizations to highlight their innovative approaches
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
Meyers, P. A., Schwartz, C. L., Krailo, M. D., Healey, J. H., Bernstein, M. L., Betcher, D., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., Harris, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.14.0095 · Cited by 752 · cited 1×
“Indeed, similar results with LMTP-PE have been observed in both dogs and children [24,25].”
ResultEconomics of New Oncology Drug Development
DiMasi, J. A., & Grabowski, H. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0803 · Cited by 348 · cited 2×
“Data for transition rates and costs of Phase I, II, and III trials are based on published cost estimates [3] and reported clinical phase transition probabilities for investigational oncology compounds from the 20 largest firms (by pharmaceutical sales in 2005) from 1993 to 2002 [2,4].”
Background
Cited by
Advancing therapy for osteosarcoma
Gill, J., & Gorlick, R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00519-8 · Cited by 876
Designing a broad-spectrum integrative approach for cancer prevention and treatment
Block, K. I., Gyllenhaal, C., Lowe, L., Amedei, A., Amin, A. R. M. R., Amin, A., Aquilano, K., Arbiser, J., Arreola, A., Arzumanyan, A., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.09.007 · Cited by 300
Canine tumors: a spontaneous animal model of human carcinogenesis
Pinho, S. S., Carvalho, S., Cabral, J., Reis, C. A., & Gärtner, F. (2012) · Translational Research · doi:10.1016/j.trsl.2011.11.005 · Cited by 289
Canine Osteosarcoma: A Naturally Occurring Disease to Inform Pediatric Oncology
Fenger, J. M., London, C. A., & Kisseberth, W. C. (2014) · ILAR Journal · doi:10.1093/ilar/ilu009 · Cited by 248
Osteosarcoma: Accelerating Progress Makes for a Hopeful Future
Saraf, A. J., Fenger, J. M., & Roberts, R. D. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00004 · Cited by 237
“Many hope that broader implementation of integrated drug development (using canine patients) will reduce regulatory burdens, financial costs, and clinical timelines in ways that accelerate the identification of more effective approaches (69).”
BackgroundGardner, H. L., Fenger, J. M., & London, C. A. (2016) · Annual Review of Animal Biosciences · doi:10.1146/annurev-animal-022114-110911 · Cited by 215
The dog aging project: translational geroscience in companion animals
Kaeberlein, M., Creevy, K. E., & Promislow, D. E. L. (2016) · Mammalian Genome · doi:10.1007/s00335-016-9638-7 · Cited by 174
“comparative oncology consortium (Gordon et al. 2009), not only for the sake of identifying better treatments for canine cancer (Thamm and Vail 2015), but also for their translational potential (Paoloni and Khanna 2008).”
BackgroundConcise Review: Stem Cell Trials Using Companion Animal Disease Models
Hoffman, A. M., & Dow, S. W. (2016) · Stem Cells · doi:10.1002/stem.2377 · Cited by 167
Perspectives from man’s best friend: National Academy of Medicine’s Workshop on Comparative Oncology
LeBlanc, A. K., Breen, M., Choyke, P., Dewhirst, M., Fan, T. M., Gustafson, D. L., Helman, L. J., Kastan, M. B., Knapp, D. W., Levin, W. J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf0746 · Cited by 147
“To date, the program has completed 12 multicenter clinical trials in pet dogs with spontaneous cancers, conducted through its clinical trial network, the Comparative Oncology Trials Consortium (NCI-COTC) (http://ccr. cancer.gov/resources/cop/COTC.asp), which consists of 20 academic veterinary teaching hospitals across…”
BackgroundInfluentialSelf-citationConsiderations in the extrapolation of drug toxicity between humans and dogs
Martinez, M. N., Mochel, J. P., & Pade, D. (2020) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2020.05.005 · Cited by 9
“murine models, cancers develop spontaneously in dog s [56,57]”
Background
Metadata
- Authors
- Gordon, I., Paoloni, M., Mazcko, C., & Khanna, C.
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-10-13
- Volume
- 6
- Issue
- 10
- Pages
- e1000161
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2019637349
- Cited by
- 241
- References
- 3
- FWCI
- 6.35
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.